Premium
Failure to improve cigarette smoking abstinence with transdermal selegiline + cognitive behavior therapy
Author(s) -
Killen Joel D.,
Fortmann Stephen P.,
Murphy Greer M.,
Hayward Chris,
Fong Dalea,
Lowenthal Kimberly,
Bryson Susan W.,
Killen Diana T.,
Schatzberg Alan F.
Publication year - 2010
Publication title -
addiction
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.424
H-Index - 193
eISSN - 1360-0443
pISSN - 0965-2140
DOI - 10.1111/j.1360-0443.2010.03020.x
Subject(s) - selegiline , abstinence , placebo , medicine , smoking cessation , transdermal , anesthesia , psychiatry , pharmacology , parkinson's disease , alternative medicine , disease , pathology
Aims To examine the effectiveness of transdermal selegiline for producing cigarette smoking abstinence. Design Adult smokers were randomly assigned to receive selegiline transdermal system (STS) or placebo given for 8 weeks. All participants received cognitive behavior therapy (CBT). Follow‐ups were conducted at 25 and 52 weeks. Setting Community smoking cessation clinic. Participants 243 adult smokers (≥18 years of age; ≥10 cigarettes/day). Measures Expired‐air carbon monoxide confirmed 7‐day point prevalence abstinence. Findings STS was not superior to placebo. More women than men were abstinent at 52 week follow‐up (28% vs 16%, P < 0.05). Behavioral activation (BAS) moderated treatment response ( P = 0.01). The survival rate through week 52 for those with high ‘drive’ scores on the BAS was 47% if assigned to selegiline and 34% if assigned to placebo. The survival rate for those with low ‘drive scores’ on the BAS was 35% if assigned to selegiline compared to 53% if assigned to placebo. Conclusion Transdermal selegiline does not appear generally effective in aiding smoking cessation though there may be a selective effect in those smokers with low ‘behavioral activation’.